312 related articles for article (PubMed ID: 19812602)
1. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
2. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
[No Abstract] [Full Text] [Related]
3. Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
[No Abstract] [Full Text] [Related]
4. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
6. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
7. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
8. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
9. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
[TBL] [Abstract][Full Text] [Related]
10. V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
McDonnell K; Betz B; Fullen D; Lao CD
Pigment Cell Melanoma Res; 2011 Apr; 24(2):390-2. PubMed ID: 21159146
[No Abstract] [Full Text] [Related]
11. Another option in our KIT of effective therapies for advanced melanoma.
Carvajal RD
J Clin Oncol; 2013 Sep; 31(26):3173-5. PubMed ID: 23940226
[No Abstract] [Full Text] [Related]
12. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
13. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
[TBL] [Abstract][Full Text] [Related]
14. KIT mutations in a series of melanomas and their impact on treatment with imatinib.
Botella-Estrada R; Soriano V; Rubio L; Nagore E
Actas Dermosifiliogr; 2012 Nov; 103(9):838-40. PubMed ID: 22795573
[No Abstract] [Full Text] [Related]
15. A new KIT gene mutation in thymic cancer and a promising response to imatinib.
Lim SH; Lee JY; Sun JM; Kim KM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2013 Oct; 8(10):e91-2. PubMed ID: 24457249
[No Abstract] [Full Text] [Related]
16. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb.
Yamaguchi M; Harada K; Ando N; Kawamura T; Shibagaki N; Shimada S
Clin Exp Dermatol; 2011 Mar; 36(2):174-7. PubMed ID: 20545949
[TBL] [Abstract][Full Text] [Related]
17. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate for melanoma: will a new target be revealed?
Grossman D
J Invest Dermatol; 2004 Dec; 123(6):xi-xiii. PubMed ID: 15610499
[No Abstract] [Full Text] [Related]
19. Imatinib in melanoma: a selective treatment option based on KIT mutation status?
Becker JC; Bröcker EB; Schadendorf D; Ugurel S
J Clin Oncol; 2007 Mar; 25(7):e9. PubMed ID: 17327598
[No Abstract] [Full Text] [Related]
20. A potential role for nilotinib in KIT-mutated melanoma.
Tran A; Tawbi HA
Expert Opin Investig Drugs; 2012 Jun; 21(6):861-9. PubMed ID: 22500535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]